Chapter 3: Legal & Ethical Considerations in Pharmacology

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Okay, let's unpack this.

Welcome back.

Today, we're doing a deep dive into something, well, foundational for anyone stepping into Canadian healthcare.

We're navigating the legal and ethical roadmap for pharmacology and nursing practice.

Yeah, it sounds complex and it is, but it's absolutely crucial.

Right, this isn't just memorizing rules for an exam.

It's about understanding the structure that ensures safety.

Exactly, for the patient and for you, the professional nurse.

It's about accountability.

So, our mission today.

It's really to make sense of this whole system, the federal laws, provincial regulations, the ethical side of things, and boil it down to what you really need to know for practice.

And the central theme, threading through it all.

I think it's how Canadian legislation and ethics transform just handing over a pill into a really complex professional responsibility.

You are accountable.

Got it.

So, where do we start?

Top down.

Yep, let's start right at the top.

Federal laws, that's the foundation.

Okay, so kicking things off, there are two main federal acts that really control everything drug -related in Canada.

What are they?

Right, so the big ones are the Food and Drugs Act, or FNDA, and the Controlled Drugs and Substances Act, the CDSA.

FNDA first, what's its main job?

The FNDA is basically the cornerstone of consumer safety for a whole range of products.

Drugs, food, cosmetics, medical devices.

Its main goal is protecting you, the consumer, from anything unsafe or misleading.

It covers purity, labeling, advertising, the whole package.

So, safety and truth in advertising, essentially.

Pretty much.

If it goes in you or on you, the FNDA sets the basic safety standards.

Okay, so if FNDA is about general safety and labeling, where does the CDSA come in?

It sounds more specific.

It is.

The CDSA, passed in 97, is all about substances that have a potential for misuse or abuse.

It's actually criminal law.

Ah, so this is where legality comes in possession, trafficking.

Exactly, it makes possessing, producing, trafficking, importing these controlled substances a criminal offense.

It targets the potential for harm from misuse.

And this is where we get the drug schedules, right?

That's super important for nurses on the floor.

Absolutely critical.

The CDSA categorizes these substances into schedules based on, well, how dangerous they are and their potential for abuse.

Like schedule one.

Schedule one is the highest risk category.

Think, opiates, morphine, heroin, and cocaine.

These have the strictest controls.

And for a nurse, that translates directly to?

Two procedures.

Double locking cabinets, meticulous counts every shift, needing two nurses to sign off when you waste a dose.

That federal schedule dictates your actions right at the bedside.

Makes sense.

What about other schedules?

Well, schedule three includes things like amphetamines.

Schedule four has drugs with therapeutic uses, but still significant misuse potential, like certain barbiturates or anabolic steroids.

And schedules V and six.

Those contain precursors.

The chemicals used to make controlled substances.

Important note about cannabis.

Right, good point.

Cannabis used to be under the CDSA, but now it's regulated separately under its own Cannabis Act and regulations.

Okay, so a drug meets these legal requirements.

How does Health Canada signal approved and prescription needed?

Couple of key identifiers.

First, for prescription drugs, you'll see the PR symbol.

It's that black square with white letters.

Tells you immediately, prescription only.

And the DI?

The drug identification number, or DUN.

This is huge.

Health Canada's Therapeutic Products Directorate, the TPD,

assigns this unique computer -generated number once a drug is approved for sale.

And that's on both prescription and over -the -counter meds.

Yes.

If it has a D on, it means Health Canada has reviewed its safety, efficacy, and quality.

It's the official stamp of approval.

Now, all this info, patient names, diagnoses, the drugs they're on, DANs, it's all getting digitized.

How is that patient privacy protected?

That's where privacy legislation kicks in.

Federally, we have PIPEDA, the Personal Information Protection and Electronic Documents Act.

It sets the rules for how organizations collect, use, and disclose personal information, including health information.

And provinces have their own, too.

They do.

Because health is provincial jurisdiction, most provinces have their own, often stricter, health -specific privacy laws, like Ontario has FEPA, the Personal Health Information Protection Act.

So, bottom line,

handling patient medication info is governed by strict confidentiality rules.

Absolutely.

Charting, discussing cases, even casual mentions, patient privacy is paramount, legally and ethically.

Okay, so we have these strict laws, like the FNDA.

Why so rigorous?

You mentioned a historical event really cemented this.

Yeah, the thaldimide tragedy in the early 1960s.

It's hard to overstate its impact.

The morning sickness drug.

That's the one.

Marketed for morning sickness, but it caused devastating birth defects worldwide.

Canada was affected, too.

That catastrophe really drove home the need for mandatory, thorough scientific testing before a drug hits the market.

So that led to the current stringent process overseen by Health Canada's TPD.

Exactly, the TPD acts as the gatekeeper.

Before any human testing, a potential drug undergoes extensive preclinical testing.

Which involved?

First,

in vitro studies, testing on cells or tissues in a lab.

Then, if that looks promising, extensive animal studies to assess safety, toxicity, and potential effectiveness.

Only if it clears those hurdles can they think about human trials.

Correct.

The manufacturer has to compile all that preclinical data and submit what's called an investigational new drug application, or IND application, to Health Canada.

They're basically asking permission.

Can we start testing this in people now?

Precisely.

And Health Canada reviews that IND application thoroughly.

Is there ever a fast track?

Some diseases need urgent solutions.

Yes, there's the priority review pathway.

If a drug is for a serious or life -threatening condition where there aren't good treatments available, think early HIDs drugs.

Health Canada can expedite the review.

The standard target is about 300 days, but priority review aims for 180 days.

But faster doesn't mean less thorough, right?

We learned that lesson again with Vioxx.

Absolutely not.

The Vioxx recall in 2004, due to cardiovascular risks that emerged after approval, reinforced that even post -market, vigilance is key.

Safety scrutiny never really stops.

Which brings us to the cornerstone of all human testing.

Informed consent.

This is non -negotiable.

What does that entail exactly?

It has to be completely voluntary.

The participant must fully understand the study's purpose, what procedures they'll undergo, any potential benefits, and all the known and potential risks.

And document it.

Really document it, signed consent form.

It's an ethical and legal requirement before anyone participates in any phase of clinical trials.

Okay, let's walk through those phases, four main ones.

What happens in phase one?

Phase I is small scale, usually fewer than 100 participants.

And here's the key difference.

They are typically healthy volunteers.

Healthy, not people with the disease.

Generally, yes, unless the drug is highly toxic, like some cancer drugs where it might be tested in patients from the start, but usually healthy subjects.

And the focus?

Purely safety and dosage.

What are the immediate side effects?

What's a safe dose range?

And pharmacokinetics, how the body absorbs, distributes, metabolizes, and excretes the drug.

Just the basics.

Okay, assuming it looks safe in phase one, what's next, phase two?

Right, phase two expands the numbers, maybe 100 to 300 people.

And now we involve participants who actually have the disease or condition the drug is intended to treat.

So the focus shifts.

It does.

While safety monitoring continues, the main goals here are to see if the drug actually works its effectiveness, and to refine the therapeutic dosage range.

Does it help?

At what dose?

Makes sense.

Then comes the big one, phase three.

Yeah, phase three trials are much larger.

We're talking 1 ,000 to 3 ,000 patients, often at multiple study centers, sometimes across different countries.

Why so many people?

To confirm effectiveness in a larger population, and crucially, to detect infrequent or rare adverse effects that wouldn't likely show up in smaller phase one or two groups.

This is also where we often see placebos used, right?

Correct.

Phase three is where you typically find rigorous study designs to minimize bias.

A placebo, an inactive substance that looks identical to the study drug, might be used as a control.

And blinding.

Often these are blinded studies, where the participant doesn't know if they're getting the drug or the placebo.

Even better is double blind, where neither the participant nor the investigator knows who's getting what until the study concludes.

Why double blind?

It's the gold standard for objectivity.

It prevents expectations from either the patient or the researcher from influencing the results,

minimizes bias.

So if phase three is successful,

the drug works, the side effects are acceptable,

then what?

The manufacturer gathers all the data from all phases and submits a new drug submission, NDS, to Health Canada.

It's a massive package of information.

And if Health Canada agrees.

They issue a notice of compliance, NOC, and that D9 we talked about.

The drug can now be legally marketed in Canada.

But you mentioned vigilance doesn't stop there.

What's phase four?

Phase four is post -marketing surveillance.

This happens after the drug is approved and available to the public.

Why keep testing?

To monitor its long -term safety and effectiveness in a broad, diverse population under real -world conditions.

Health Canada might require phase four studies, or the company might do them voluntarily,

maybe to compare their drug to competitors.

This is often where unexpected rare side effects or issues in specific patient groups get picked up like what happened with Vioxx.

And if serious problems emerge in phase four or through general reporting, that leads to recalls.

It can, yes.

If enough evidence of a serious problem arises, Health Canada can request or negotiate a voluntary recall with the manufacturer, or in rare cases, Mandate 1.

Are there different levels of recall severity?

Yes, three classes.

Class one is the most serious.

There's a reasonable probability the drug will cause serious health problems or even death.

These require immediate action.

Class two.

Class two means the drug might cause temporary or medically reversible health problems or the chance of serious harm is remote.

And class three.

Class three is for situations where the drug violates regulations but is unlikely to cause any significant health issues.

Maybe a labeling error.

The urgency decreases from class one to three.

One last thing in this section.

The special access program.

What's that for?

Right, the SAP.

It's a mechanism for doctors to request access to drugs that aren't yet authorized for sale in Canada.

For what kind of situations?

For patients with serious or life -threatening conditions where conventional therapies have failed or aren't suitable.

It's compassionate access, basically.

Are there limits?

Yes, it has strict criteria and it generally excludes certain unauthorized controlled substances like heroin or LSD, for example.

It's for therapeutic use under specific urgent circumstances.

Okay, so that whole intense journey preclinical phases I through IV approvals, recalls.

A drug finally makes it to the hospital or pharmacy shelf.

What does all this mean for you, the nurse standing there ready to administer it?

This is where the rubber hits the road, legally and ethically.

Your practice isn't just guided by hospital policy.

It's defined by law.

Specifically, the Nurse Practice Acts, NPAs.

Exactly.

Each province and territory has its own NPA.

These are provincial laws that regulate nursing.

They define your scope of practice, what you're legally allowed to do.

They also set out education requirements and critically establish the minimum standard of safe practice.

You must meet that standard.

And if you don't meet that standard, that's where liability comes in.

We hear terms like negligence, malpractice.

They're related, but distinct.

Negligence is a general legal concept, basically.

Failing to act as a reasonably prudent person would in a similar situation, causing harm.

Like spilling hot coffee on someone.

Could be, yeah.

It doesn't require specialized knowledge.

Malpractice, however, is specific to professionals.

How so?

Malpractice is professional negligence.

It's when a nurse, doctor, or other professional fails to meet the standard of care expected of someone with their specialized education and training, and that failure causes harm.

So, giving the wrong drug dose because you didn't follow the rights of medication administration, that's malpractice.

Precisely, because following those rights is part of the expected professional standard of care for a nurse.

The source material highlights three main areas where nurses could face liability specifically related to medications.

Let's break those down.

First,

failure to ensure safety.

What does that look like, practically?

This is about basic vigilance and following safety protocols.

It could be giving a drug despite knowing the patient has an allergy to it.

Okay.

Or using an unsafe administration technique like crushing a pill that's clearly marked do not crush because it's extended release.

It's failing to use guardrails that prevent predictable harm.

Makes sense.

The second area sounds like the most obvious one, medication errors.

Yes, and probably the most common.

This covers a lot.

Failing to document that you gave a drug, which could lead to another nurse giving it again.

Apple dosing, yeah.

Or seeing a prescription order that's unclear.

Maybe the dose looks way too high or the handwriting is illegible and just going ahead without clarifying it with the prescriber.

You have to question unclear orders.

What else falls under med errors?

Giving the wrong drug, wrong dose, wrong route, wrong time, wrong patient.

Violating any of the fundamental rights of medication administration.

Even calculation errors.

And the third area is a bit more about judgment.

Failure to assess or evaluate.

Absolutely critical.

This involves things like not getting a complete medication history before starting a new drug.

You need to know what else the patient is taking.

And after giving the drug?

It's failing to monitor the patient appropriately.

Not noticing significant changes.

Maybe there are blood pressure plummets after an antihypertensive.

Or they develop hives and difficulty breathing suggesting an allergic reaction.

And crucially, it's not just seeing the change but reporting it promptly to the prescriber or charged nurse.

Failure to assess, monitor, and report.

So constant vigilance before, during, and after administration.

That's the standard.

Now beyond these legal standards set by the NPAs, nursing practice is also deeply rooted in ethics.

What are the core principles guiding drug therapy?

These ethical principles really underpin everything.

Autonomy is huge, respecting the patient's right to make their own decisions about their care.

Including the right to refuse medication, even if you disagree.

Even if you think it's bad for them.

Even then.

As long as they have capacity to make the decision, their autonomy prevails.

Then there's beneficence, the duty to do good.

To act in the patient's best interest.

And it's counterpart?

It's non -maleficence, the duty to do no harm.

This is fundamental in medication safety.

Avoiding errors,

monitoring for side effects.

Others?

Justice, which means fairness, treating patients equitably.

Fair allocation of resources.

Fidelity, which is about being faithful to your commitments.

Keeping promises to your patients.

And veracity, which is simply truthfulness.

Being honest with patients.

Okay, let's connect those principles, especially veracity and autonomy, to a tricky issue.

Placebos.

Using them outside of a clinical trial.

Yeah, this is ethically fraught.

Outside of a properly consented research study, giving a patient a placebo, like a sugar pill, without their knowledge, is generally considered unethical.

Why specific?

It directly violates veracity you're deceiving the patient.

And it undermines autonomy because they haven't consented to receiving an inactive substance.

It fundamentally damages trust.

Is it ever, okay?

It's highly debatable.

Some limited research suggests potential ethical use in very specific context, like chronic pain under strict conditions, with patient awareness of potential placebo use.

But as a general rule in standard practice,

no.

So if a nurse sees an order for a placebo outside of a research trial.

Your ethical and professional duty is to question that order.

You need to understand the rationale and likely advocate for the patient against deceptive practice.

Goes back to that core principle of trust.

That really emphasizes the nurse's role as advocate using both legal standards and ethical principles.

Hashtag outro outro.

All right, so we've covered a lot of ground.

We mapped the legal framework,

the strict federal oversight with the FNDA and CDSA, setting safety and control standards.

We walked through that rigorous drug approval process phases, I through 5E, all anchored by that critical element of informed consent.

Right, and the provincial NPA is setting the minimum legal standards for your nursing practice.

And we looked at where liability can arise, failure in safety, medication errors, or inadequate assessment and evaluation.

And tying it all together are those core ethical principles.

Autonomy, beneficence, non -maleficence, justice, fidelity, veracity.

They guide every decision.

Now looking ahead, nurses are gaining more autonomy in some areas, even prescribing authority in certain specialties in some provinces.

That seems to demand an even deeper grasp of all these principles we've discussed.

Absolutely, more autonomy means more responsibility, legally and ethically.

But here's a final thought to chew on.

We have this complex system for ensuring drug safety and efficacy, yet many prescription drugs aren't covered by the Canada Health Act.

Access is a huge issue for many Canadians due to costs.

That's a major tension.

So how does that reality, the financial barriers, the complexity of navigating access challenge your role as a nurse, trying to advocate for your patient within this legal and ethical framework?

That intersection of professional responsibility,

ethics,

and the socioeconomic realities of healthcare access, that's definitely something worth pondering as you move forward in your practice.

A complex question with no easy answer.

Thank you for joining us on this Deep Dive.

We really hope breaking down this framework helps you navigate your responsibilities confidently.

A warm thank you from the Deep Dive team.